Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity
Authors' conclusion
Weight loss with cotadutide is primarily driven by reduced EI, with relatively small compensatory changes in EE.
Study context
- Population
- Overweight and obese adults with T2Drandomized 2:1
- Comparison
- Cotadutide vs placebo
- Primary endpoint
- Percentage weight change
Methodological detailsphase 2a, single-centre, placebo-controlled, double-blind, 16-day single-blind placebo run-in, Completed: 12 (63%) cotadutide, 7 (78%) placebo
- Phase 2a
- Single-centre
- Placebo-controlled
- Double-blind
- 16-day single-blind placebo run-in
- Completed: 12 (63%) cotadutide, 7 (78%) placebo
Primary result
As reported in the abstract
Weight change
Cotadutide
−4.0%
mean · 90% CI −4.9%–-3.1%
Placebo
−1.4%
mean · 90% CI −2.7%–-0.1%
P = 0.011
Secondary outcomes
| Outcome | Difference, % | P value | |
|---|---|---|---|
| Energy intake | −41.3 (CI −66.7 to −15.9) | P = 0.011 | |
| EE (per kJ/kg lean body mass), doubly labelled water | 1.0 (90% CI −8.4 to 10.4) | P = 0.784 | |
| EE (per kJ/kg lean body mass), indirect calorimetry | −6.5 (90% CI −9.3 to −3.7) | P < 0.001 | |
| −100−50050Difference, % (linear scale) |
Original publication
Dual glucagon‐like peptide ‐1 and glucagon receptor agonism reduces energy intake in type 2 diabetes with obesity. Diabetes Obes Metab. Published 1 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →